86 related articles for article (PubMed ID: 31695339)
21. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy.
Schiel R; Ulbrich S; Müller UA
Diabetes Metab; 1998 Dec; 24(6):509-14. PubMed ID: 9932217
[TBL] [Abstract][Full Text] [Related]
22. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
[TBL] [Abstract][Full Text] [Related]
23. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
[TBL] [Abstract][Full Text] [Related]
24. Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study.
Davis TM; Davis Cyllene Uwa Edu Au WA; Bruce DG
Med J Aust; 2006 Apr; 184(7):325-8. PubMed ID: 16584365
[TBL] [Abstract][Full Text] [Related]
25. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
26. Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.
Bonora BM; Rigato M; Frison V; D'Ambrosio M; Tadiotto F; Lapolla A; Simioni N; Paccagnella A; Avogaro A; Fadini GP
Diabetes Res Clin Pract; 2021 Mar; 173():108686. PubMed ID: 33548335
[TBL] [Abstract][Full Text] [Related]
27. Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study.
de Valk HW; Feher M; Hansen TK; Jendle J; Koefoed MM; Rizi EP; Zimmermann E; Fadini GP
Diabetes Ther; 2020 Sep; 11(9):2159-2167. PubMed ID: 32666165
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported racial/ethnic healthcare provider discrimination and medication intensification in the Diabetes Study of Northern California (DISTANCE).
Lyles CR; Karter AJ; Young BA; Spigner C; Grembowski D; Schillinger D; Adler N
J Gen Intern Med; 2011 Oct; 26(10):1138-44. PubMed ID: 21547610
[TBL] [Abstract][Full Text] [Related]
29. Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.
Brunton SA; Kruger DF; Funnell MM
Clin Diabetes; 2016 Jan; 34(1):34-43. PubMed ID: 26807007
[TBL] [Abstract][Full Text] [Related]
30. A Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications.
Pilla SJ; Meza KA; Schoenborn NL; Boyd CM; Maruthur NM; Chander G
J Gen Intern Med; 2023 Mar; 38(4):1008-1015. PubMed ID: 36175758
[TBL] [Abstract][Full Text] [Related]
31. Reasons for non-intensification of treatment in people with type 2 diabetes receiving oral monotherapy: Outcomes from the prospective DIAttitude study.
Balkau B; Halimi S; Blickle JF; Vergès B; Avignon A; Attali C; Chartier I; Amelineau E
Ann Endocrinol (Paris); 2016 Dec; 77(6):649-657. PubMed ID: 27646493
[TBL] [Abstract][Full Text] [Related]
32. A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA.
Rattelman CR; Ciemins EL; Stempniewicz N; Mocarski M; Ganguly R; Cuddeback JK
Diabetes Ther; 2021 Feb; 12(2):581-594. PubMed ID: 33460018
[TBL] [Abstract][Full Text] [Related]
33. Assessment and prevention of hypoglycaemia in primary care among U.S. Veterans: a mixed methods study.
Pilla SJ; Meza KA; Beach MC; Long JA; Gordon HS; Bates JT; Washington DL; Bokhour BG; Tuepker A; Saha S; Maruthur NM
Lancet Reg Health Am; 2023 Dec; 28():100641. PubMed ID: 38076413
[TBL] [Abstract][Full Text] [Related]
34. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
36. De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study.
Hart HE; Ditzel K; Rutten GE; de Groot E; Seidu S; Khunti K; Vos RC
Patient Prefer Adherence; 2019; 13():1775-1783. PubMed ID: 31695339
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
